Speaker
David R. Vera
(Univeristy of California S. Diego)
Description
Tilmanocept is a synthetic molecular radiopharmaceutical designed to minimize the limitations of currently used agents for sentinel lymph node identification. Its molecular properties and specific receptor binding allow for improved lymphatic entrance and high retention in the sentinel node, ultimately allowing for an improvement in the accuracy of cancer staging in diseases that utilize sentinel lymph node mapping. It avoids dangers associated with the use of human-derived substances. Furthermore, its chemical properties allow for attachment of additional imaging reporters, permitting future multi-modal imaging of the sentinel lymph node via a molecular target.
